Adalimumab Biosimilar Market Size to Grow by USD 5,253.8 Mn by 2032 | Expected YOY of 23.9%
Market Overview As a result of the Ukraine-Russia War and COVID-19 epidemic, The global adalimumab biosimilar market is projected to be USD 598.3 Mn in 2022 to reach USD 5,253.8 Mn by 2032 at a CAGR of 23.9%. This is the best medium to know more about market scenario. Adalimumab is a biologic drug used for the treatment of various chronic inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. It is a recombinant human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α). The report's greatest asset is its ability to provide organizations…
- Date: August 17, 2022
- Author: Quintero
- Category: Taiwan News